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Objective To investigate the presence of the genome of GB virus C/hepatitis G virus
(GBV-C/HGV) in semen and saliva from HIV-1-infected men.
Methods Samples of blood from 33 men seropositive for HIV-1 were tested for the
presence of GBV-C/HGV markers of infection, RNA by RT-PCR, and anti-E2 antibodies
by ELISA, respectively. The cell-free fractions of seminal fluid and saliva samples of the
patients with positive blood samples for GBV-C/HGV RNA or anti-E2 antibodies were
then analyzed for the presence of the RNA of this virus. In addition, six semen samples
and 11 saliva samples from GBV-C/HGV-negative men were tested.
Results The GBV-C/HGV RNA tested by RT-PCR was recovered from blood in 11
patients of 33 (33.3%), and the antibodies to E2 envelope protein were detected in six
patients (18.2%). Since no patient was positive for both markers, the overall prevalence of
GBV-C/HGV infection was 51.5% in the studied population. Four—all belonging to the
homosexual risk group—of the 17 men with markers to GBV-C/HGV in blood were
found to be positive for GBV-C/HGV RNA in mucosal samples: two of them exhibited
genomic RNA in both semen and saliva, and two others were positive for semen only.
The absence of inhibitors of the PCR technique was confirmed in all mucosal fractions
found negative for GBV-C/HGV RNA, except for one saliva sample and one seminal
fluid sample.
Conclusion These results confirm the high prevalence of GBV-C/HGV infection in
patients infected with HIV-1 by sexual exposure and the presence of GBV-C/HGV
RNA in seminal fluid and saliva of men with markers of this virus in the blood,
suggesting that mucosal fluids could be a potential source for the spread of the GBV-
C/HGV infection.
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I N T R O D U C T I O N
GB virus C–hepatitis G virus (GBV-C/HGV) is a
recently described flavivirus [1,2] that has not yet
been related clearly to any hepatic disorder and
whose pathogenicity in humans is still disputed.
The natural history of the infection by this agent is
now well understood: after a period of viremia,
which may last several months or years, GBV-C/
HGV RNA disappears from the blood and is
replaced by protective antibodies directed to the
viral envelope (anti-E2 antibodies) [3]. When both
direct and indirect markers of GBV-C/HGV infec-
tion are taken into consideration, the prevalence of
this infection in the general population is high, as
illustrated by figures of 5.5% and 10.4% in US and
German blood donors, respectively [4,5]. These
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results suggest that, besides the well recognized
parenteral modes of transmission via blood pro-
ducts or intravenous drug injection, more common
sources of contamination exist. Recently, consider-
able evidence has accumulated on the probable
transmission of GBV-C/HGV via the sexual route
[6–12]. However, very few studies have dealt with
direct detection of viral RNA in genital samples,
and they have displayed contradictory results
[13,14]. In the present study, we investigated
semen and saliva specimens from men infected
with the human immunodeficiency type 1 virus
(HIV-1) for the presence of GBV-C/HGV RNA;
our results show that the viral genome may be
found in mucosal samples during the viremic
stage of GBV-C/HGV infection.
M A T E R I A L S A N D M E T H O D S
Patients
Thirty-three HIV-1-seropositive men followed at
the Hospital of Saint-Etienne were included in the
study, between January 1998 and October 1999; all
gave their written informed consent to provide
blood, semen and saliva samples. The risk factors
for HIV-1 contamination, taken from the French
DMI2 database, were sexual exposure in 27 sub-
jects (18 homosexual, two bisexual and five hetero-
sexual men), parenteral exposure in three subjects
(intravenous drug users), and unknown in three
subjects. At the time of the study, the age mean
( SD) and the mean of CD4þ count ( SD) were
41 years ( 9) and 401/mm3 ( 262), respectively.
No patient had received an immunoglobulin regi-
men at the time of the study.
Samples
Samples of peripheral blood, saliva and semen
were processed within 4 h of collection. The
plasma fraction of blood was stored at80 8C until
use. After a 1 : 1 dilution (v/v) of semen and saliva
samples in complete phosphate-buffered saline
(PBS), the cell-free fractions were obtained after
centrifugation for 30 min at 400g and stored at
80 8C until processing. The plasma samples were
first tested for GBV-C/HGV RNA and anti-E2
antibodies. Then, the cell-free fractions of seminal
fluid and saliva from those patients found positive
for GBV-C/HGV markers in blood were analyzed
by the GBV-C/HGV RT-PCR assay. In addition,
six semen and 11 saliva samples from 13 patients
negative for GBV-C/HGV markers in blood were
tested by the same assay as controls.
HGV/GBV-C RT-PCR assay
For the technique applied for the extraction,
reverse transcription, amplification and detection
steps of GBV-C/HGV, we used reagents provided
by Boehringer-Mannheim (Meylan, Germany).
Briefly, 400 mL of the cell-free fractions of semen
and saliva was centrifuged at 100 000g for 1 h; the
pellets were used for RNA extraction using the
High Pure Viral Nucleic Acid kit. The same kit was
used for extraction of viral RNA from 200 mL of
plasma, as recommended by the manufacturer.
Then, all RNA samples were reverse-transcribed
and amplified in a one-step reaction using the
Titan RT-PCR system and two primers specific
for the 50-non-coding region of GBV-C/HGV gen-
ome (primer sense 50-CGG CCA AAA GGT GGT
GGA TG-30, and antisense 50-CGA CGA GCC TGA
CGT CGG G-30) [15] in a Gene Amp 9600 thermal
cycler (Perkin-Elmer, Saint-Quentin en Yvelines,
France). After a reverse transcription step at 50 8C
for 30 min and 94 8C for 2 min, 40 cycles were
performed, consisting of denaturation (94 8C for
30 s), annealing (55 8C for 30 s) and extension (68 8C
for 30 s), followed by an extension step at 68 8C for
7 min. The detection of the digoxigenin-labeled
products was performed by using the PCR ELISA
DIG Detection Kit: PCR products were hybridized
with a specific biotinylated probe for the 50-non-
coding region (50-biotin-GGT AGC CAC TA-
T AGG TGG G-30). After binding to a streptavi-
din-coated solid phase had taken place, the
reaction was revealed by using an antidigoxigenin
peroxidase conjugate.
Assay for RT-PCR inhibitors
In order to validate the negative results obtained in
seminal and saliva samples, 350 mL of cell-free
fraction from each seminal and saliva sample
was spiked with 50 mL of a GBV-C/HGV RNA-
positive sample obtained from a chronically
infected patient. The samples were then processed
as described above. All the positive samples from
patients detected as positive for GBV-C/HGV
RNA in semen and saliva were tested again after
serial two-fold dilutions from 1 : 1 to 1 : 8 in PBS in
order to check the sensitivity of the PCR assay in
plasma, semen and saliva.
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Anti-E2 antibody detection
Antibodies to GBV-C/HGV E2 antigen were
tested by ELISA using the mPlate anti-HGenv assay
(Boehringer-Mannheim) [3] according to the man-
ufacturer’s instructions.
Determination of HIV-1 viral RNA loads
All the plasma samples were tested for the quan-
tification of HIV-1 by the HIV-1 Monitor Assay
(Roche Diagnostics, Meylan, France).
Hepatitis C antibody detection
Antibodies to HCV were evaluated by a commer-
cially available ELISA technique (AXSYM, Abbott
Diagnostics, Rungis, France).
R E S U L T S
Prevalence of viremia and anti-E2 antibodies to
GBV-C/HGV in blood
GBV-C/HGV RNA was detected in the plasma of
11 of 33 patients seropositive for HIV-1. The detec-
tion of anti-E2 antibodies was positive in six of 33
men. Since no subject was positive for both GBV-
C/HGV markers, the overall prevalence of infec-
tion by this virus in the studied HIV-1 population
was 17 of 33 (51.5%). The identified risk for HIV-1
contamination in these 17 subjects was as follows:
the sexual route in 15 cases (13 homosexuals, two
heterosexuals), intravenous drug abuse in one
case, and not determined in the last case.
Detection of GBV-C/HGV RNA in mucosal
samples
Seminal fluid and saliva specimens from the 17
patients positive in plasma for one marker of
GBV-C/HGV infection were tested for the pre-
sence of GBV-C/VHG RNA by RT-PCR assay.
Four of 16 seminal fluids (25%) and two of 16
saliva specimens (12.5%) were found to be posi-
tive, since PCR inhibitors were detected in only
one semen sample and one saliva sample, respec-
tively (Table 1). However, it is clear that the sensi-
tivity of the test in mucosal samples was not as
good as in plasma, since a reference positive
plasma sample diluted 1 : 8 in each negative muco-
sal specimen gave mean optical densities (OD) of
0.84 0.44 for seminal fluids and 0.92 0.54 for
saliva, compared to an OD of 1.82 for the plasma
sample diluted 1 : 8 in PBS. After serial two-fold
dilutions of the plasma, semen and/or saliva
from the same patient, the amount of GBV-C/
HGV RNA detected in mucosal samples was
greatly reduced as compared to plasma, with
differences of ranges from 2 to 3 log2 (Table 2).
The specificity of the test was assayed in six
seminal fluids and 11 salivas taken from 13
patients who tested negative in blood for GBV-
C/HGV markers; all these samples were negative
(Table 1).
Individual data of patients positive for GBV-C/
HGV RNA in mucosal samples
Table 2 illustrates the individual data for the four
subjects found positive for GBV-C/HGV RNA in
mucosal samples. All of them belonged to the
homosexual risk group for HIV-1 infection, were
negative for hepatitis C infection, and exhibited
GBV-C/HGV viremia. It is worth noting that the
two patients who were positive for GBV-C/HGV
RNA in saliva samples were also positive for this
agent in semen. In addition, the oldest serum
specimen available from each of these four
patients was tested retrospectively for the detec-
tion of GBV-C/HGV RNA: all samples were found
Table 1 General characteristics of 33 HIV-1-infected patients and detection of GBV-C/HGV RNA in their mucosal samples
according to the GBV-C/HGV status in plasma
Number of patients
with GBV-C/HGV
RNA inGVB-C/VHG status
in plasma
RNA/anti-E2 antibodies
Number of
patients
(n¼ 33)
Age
in years
(mean  SD)
CD4 cell
count/mm3
(mean  SD)
HIV viremia
log copies/mL
(mean  SD) Semen Saliva
þ/– 11 37 8 432 221 3.57 0.89 4 2
–/þ 6 41 8 448 353 3.48 0.91 0 0
–/– 16 43 9 361 263 3.69 0.80 0a 0b
aSix samples tested. bEleven samples tested.
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to be positive at the beginning of the follow-up,
corresponding to durations of the GBV-C/HGV
viremia of at least 43, 15, 3.5 and 19 months for
patients 1, 2, 3 and 4 (as numbered in Table 2),
respectively.
As compared to the 11 patients with GBV-C/
HGV markers in blood but negative for viral RNA
in mucosal samples, the four patients listed in
Table 2 were younger (32 6 versus 42 8 years,
P< 0.03 by Student’s t-test); no statistically signif-
icant difference was noted between these two
groups in terms of CD4 cell count (551 348
cells/mm3 versus 380 249) and HIV viral load
(3.25 1.01 versus 3.76 0.85 log copies/mL).
D I S C U S S I O N
The main objective of this study was to evaluate
the prevalence of GBV-C/HGV RNA in mucosal
samples of HIV-1-positive patients with markers
of GBV-C/HGV infection in plasma: four of 11
patients with viremia were also positive in semen
(36.4%) versus none of six patients with antibodies
to E2 protein. To our knowledge, this study is the
third one to deal with this problem. The first two
reports [13,14] gave conflicting results: Semprini
et al. were able to detect GBV-C/HGV RNA in six
of 12 patients, while Hollingsworth et al. did not
find GBV-C/HGV RNA in semen of eight HIV-1-
positive men exhibiting GBV-C/HGV viremia.
Concerning the four positive patients of the pre-
sent study, it is interesting to note that they all
belonged to the homosexual risk group and that
the viremia had lasted from 3.5 to 43 months.
These findings constitute additional evidence for
the transmission of GBV-C/HGV by the sexual
route. It is probable that the sensitivity of the test
was impaired by the presence of PCR inhibitors in
seminal fluid (Semprini et al. [14] and this study),
and that the proportion of patients actually
infected in seminal fluid could have been higher
with a more accurate test. In contrast, the absence
of detection of GBV-C/HGV RNA in the semen of
subjects with anti-E2 antibodies suggests that the
presence of this virus in semen is mostly contem-
porary with persistent infection in blood. This
observation is not surprising, since it is now clearly
proven that anti-E2 antibodies are detected after
viral clearance from the blood [3].
Another interesting finding of this study is the
detection of GBV-C/HGV RNA in saliva in two of
the patients found to be infected by this virus inT
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blood and seminal samples. Although the excre-
tion of GBV-C/HGV in saliva has already been
reported in two recent studies [16,17], this is the
first time that simultaneous infections by this virus
in blood, semen and saliva have been reported. As
noticed in the two former studies [16,17], the PCR
signal detected in saliva was considerably lower
than that in the corresponding plasma. The weak
sensitivity of the PCR assay in negative mucosal
samples spiked with GBV-C/HGV RNA suggests
that the presence of PCR inhibitors in saliva is
responsible, at least in part, for this observation.
Similar conclusions can be drawn from the results
obtained in seminal samples.
Although the detection of GBV-C/HGV
sequences in body fluids does not necessarily
imply infectivity, especially when low signals
are obtained, our data merely support the hypoth-
esis of sexual and/or oral transmission of this
virus, at least in HIV-1-infected subjects. Similar
studies in HIV-negative men would be useful to
address whether the relatively high prevalence of
GBV-C/HGV RNA in mucosal fluids obtained in
this work is related to higher blood viral loads in
HIV/GBV-C/HGV-coinfected patients, as already
observed for HCV viral load in blood in HIV/HCV
coinfection [18].
In addition, the consequence of persisting infec-
tion by GBV-C/HGV at the mucosal level in HIV-
1-infected subjects needs to be studied more exten-
sively, especially in the light of recent reports [19–
21] suggesting that the carriage of GBV-C/HGV
RNA in blood is associated with a slower progres-
sion of HIV disease.
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